Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection

Overview

Journal Nature

Specialty Science

Date 1995 Jan 12

PMID 7816094

Citations 1194

Authors

D D Ho

A U Neumann

A S Perelson

W Chen

J M Leonard

M Markowitz

Affiliations

Soon will be listed here.

Abstract

Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.

Citing Articles

Tracking HIV persistence across T cell lineages during early ART-treated HIV-1-infection using a reservoir-marking humanized mouse model.

Satija N, Patel F, Schmidt G, Doanman D, Kapoor M, La Porte A Nat Commun. 2025; 16(1):2233.

PMID: 40044684 PMC: 11883074. DOI: 10.1038/s41467-025-57368-7.

HIV-1 resistance mutations and genetic diversity among children failing antiretroviral treatment in five healthcare facilities in Benin, West Africa.

Dagba Gbessin E, Tchiakpe E, Keke R, Vidal N, Gomgnimbou M, Sina H PLoS One. 2025; 20(1):e0317882.

PMID: 39879199 PMC: 11778783. DOI: 10.1371/journal.pone.0317882.

Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-omicron or omicron variants: a modelling analysis of the randomized DisCoVeRy trial-authors' response.

Beaulieu M, Guedj J J Antimicrob Chemother. 2025; 80(3):892-893.

PMID: 39799974 PMC: 11879190. DOI: 10.1093/jac/dkae447.

Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies.

Barger L, El Naggar O, Ha B, Romano G Cancer Metastasis Rev. 2024; 44(1):9.

PMID: 39609320 PMC: 11604825. DOI: 10.1007/s10555-024-10230-6.

Pro-inflammatory macrophages suppress HIV replication in humanized mice and co-cultures.

Baroncini L, Muller C, Kadzioch N, Wolfensberger R, Russenberger D, Bredl S Front Immunol. 2024; 15:1439328.

PMID: 39575258 PMC: 11578737. DOI: 10.3389/fimmu.2024.1439328.